Celcuity (CELC) Projected to Post Quarterly Earnings on Thursday

Key Points

• Celcuity is expected to release its Q2 2025 earnings on August 13th, with analysts predicting earnings of ($0.94) per share.
• In a notable recent transaction, Director David Dalvey sold 100,000 shares of the company’s stock, reducing his ownership by 44.44%.
• Analysts have given Celcuity a consensus target price of $39.20, with several firms issuing "buy" ratings and price targets ranging from $29.00 to $60.00.

Celcuity (NASDAQ:CELC - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.94) per share for the quarter.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.09. On average, analysts expect Celcuity to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Celcuity Trading Up 3.7%

Celcuity stock traded up $1.64 during midday trading on Friday, reaching $45.88. The stock had a trading volume of 1,325,977 shares, compared to its average volume of 2,577,971. The firm's fifty day simple moving average is $18.60 and its two-hundred day simple moving average is $13.44. Celcuity has a twelve month low of $7.57 and a twelve month high of $48.00. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.61 and a quick ratio of 6.61. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -15.14 and a beta of 0.68.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Stifel Nicolaus assumed coverage on shares of Celcuity in a research note on Tuesday, July 1st. They issued a "buy" rating and a $30.00 price objective for the company. Leerink Partners raised their price objective on shares of Celcuity from $28.00 to $60.00 and gave the stock an "outperform" rating in a research note on Monday, July 28th. HC Wainwright raised their price objective on shares of Celcuity from $27.00 to $50.00 and gave the stock a "buy" rating in a research note on Monday, July 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Celcuity in a research note on Monday, July 28th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Celcuity presently has a consensus rating of "Buy" and a consensus target price of $39.20.

Insider Activity

In other Celcuity news, Director David Dalvey sold 100,000 shares of Celcuity stock in a transaction on Monday, July 28th. The shares were sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the completion of the sale, the director owned 125,000 shares of the company's stock, valued at $5,497,500. This trade represents a 44.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 15.77% of the stock is owned by company insiders.

Institutional Investors Weigh In On Celcuity

An institutional investor recently bought a new position in Celcuity stock. Creative Planning bought a new position in Celcuity, Inc. (NASDAQ:CELC - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 13,291 shares of the company's stock, valued at approximately $177,000. Institutional investors own 63.33% of the company's stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.